Irritable bowel syndrome (IBS) is a functional bowel disorder (that is, not associated with structural or bio chemical abnormalities that are detectable with the cur rent routine diagnostic tools) characterized by abdominal pain or discomfort, stool irregularities and bloating (BOX 1). Symptoms can be debilitating in many individ uals, but may be mild or moderate in other patients. In addition, IBS is often associated with other somatic comorbidities (for example, pain syndromes, overactive bladder and migraine), psychiatric conditions (includ ing depression and anxiety) and visceral sensitivity. The population prevalence of IBS is high (~11%) and the condition has considerable consequences for quality of life (QOL) that are comparable to other chronic diseases, such as diabetes mellitus and hepatitis. IBS is diagnosed based on symptoms, and a distinction is made between the following subtypes of IBS: IBS with pain or discom fort and predominant constipation (IBSC), IBS with diarrhoea (IBSD), mixed IBS (IBSM) and unsubtyped IBS (IBSU) (FIG. 1) . Moreover, other diseases (including other functional gastrointestinal diseases, such as func tional dyspepsia and gastroesophageal reflux disease) that may cause the typical IBS symptoms should be excluded. Although a substantial proportion of patients will experi ence spontaneous remission over time, there is currently no treatment that cures IBS; relief of symptoms is the most that can be achieved.
Irritable bowel syndrome (IBS) is a functional bowel disorder (that is, not associated with structural or bio chemical abnormalities that are detectable with the cur rent routine diagnostic tools) characterized by abdominal pain or discomfort, stool irregularities and bloating
. Symptoms can be debilitating in many individ uals, but may be mild or moderate in other patients. In addition, IBS is often associated with other somatic comorbidities (for example, pain syndromes, overactive bladder and migraine), psychiatric conditions (includ ing depression and anxiety) and visceral sensitivity. The population prevalence of IBS is high (~11%) and the condition has considerable consequences for quality of life (QOL) that are comparable to other chronic diseases, such as diabetes mellitus and hepatitis. IBS is diagnosed based on symptoms, and a distinction is made between the following subtypes of IBS: IBS with pain or discom fort and predominant constipation (IBSC), IBS with diarrhoea (IBSD), mixed IBS (IBSM) and unsubtyped IBS (IBSU) (FIG. 1) . Moreover, other diseases (including other functional gastrointestinal diseases, such as func tional dyspepsia and gastroesophageal reflux disease) that may cause the typical IBS symptoms should be excluded. Although a substantial proportion of patients will experi ence spontaneous remission over time, there is currently no treatment that cures IBS; relief of symptoms is the most that can be achieved.
IBS is a multifactorial disease. Hence, the under lying pathogenesis is considered complex and the pre cise molecular pathophysiology is far from understood. Several functional alterations have been described, such as altered visceral sensitivity, functional brain alterations, bowel motility and secretory dysfunctions, and somatic and psychiatric comorbidities. Furthermore, gastroin testinal abnormalities -such as immune activation, gut dysbiosis (microbial imbalance), impaired mucosal functions, nerve sensitization, postinfectious plasticity, altered expression and release of mucosal and immune mediators, and altered gene expression profiles -have been associated with IBS. However, a coherent link between particular pathologies and IBS symptoms is yet to be established.
Moreover, results from studies assessing the contrib ution of most of the proposed pathological factors are inconsistent and the particular aetiology is often not related to particular gut symptoms. For example, some studies have found evidence for gut micro inflammation in IBS, whereas others could not confirm this finding, despite similar gastrointestinal symptoms. Such dis crepancies, which also apply to the other biomarker candidates (not only to inflammation), strongly sug gest the existence of IBS subpopulations, which, despite the similar ity in gut symptoms, can be defined and distinguished by their pathophysiology and indepth assessments of clinical and molecular biomarker clus ters. The same heterogeneity is evident with respect to clinical diagnosis and management. Indeed, medical treatment, nutritional intervention and psychotherapy lack consistent and homogeneous efficacy, but can be effective in some subgroups.
This Primer summarizes recent progress in our understanding of IBS prevalence, comorbidities, QOL and the putative roles of inflammation, genet ics, the intestinal microbiota and the brain-gut axis in IBS pathogenesis. Furthermore, we will discuss the current diagnostic approach and highlight the thera peutic options in IBS, including drugs, nutrition and psychotherapy.
Epidemiology

Global prevalence and incidence
Prevalence rates of IBS vary between 1.1% and 45%, based on population studies from countries world wide (FIG. 2;  Supplementary information S1 (table)), with a pooled global prevalence of 11.2% (95% CI: 9.8-12.8) 1 . Prevalence rates of 5-10% are reported for most European countries, the United States and China 1 . Population statistics for IBS in most African and many Asian countries are unavailable, which might point to the inability to differentiate between infectious diarrhoea and IBS in tropical countries, especially in those nations with poor healthcare systems or limited patient access to medical care, or to less attention of the healthcare system for functional disorders, once an acute infection has been excluded 2 .
Gathering subtypespecific prevalence information is complex. IBS subtypes overlap considerably in terms of symptoms, and patients vary over time in terms of their predominant symptoms, and thus switch subtype 3 . The few population studies that have differentiated between IBS subtypes suggest that, in countries with a total IBS prevalence of ~10%, IBSC and IBSD each account for onethird of the affected population 4 . Incidence rates of IBS (that is, the annual occurrence of new cases) are not reported for most countries, but a few longterm sur veys (≥10 years) in the United States allow for an esti mation of the annual incidence in the range of 1-2% 5 . At the same time, disappearance rates of 2% have been reported 6 , indicating spontaneous disease remission.
Association between IBS and other disorders
Not only do IBS subtypes overlap 6 but populationbased studies also report a substantial overlap of ≥20% with other functional gastrointestinal disorders of the upper and lower gastrointestinal system: functional dyspepsia, heartburn, gastroesophageal reflux disease and nausea on the one hand 7 , and diarrhoea, incontinence, pelvic floor dyssynergia and constipation on the other hand 8 . An overlap of IBS with inflammatory bowel diseases (IBDs; including Crohn disease and ulcerative colitis) during remission phases has been proposed 9 but is not mutually agreed on 10 .
Other IBSassociated disorders (FIG. 3) include func tional nongastrointestinal syndromes, such as uro logical chronic pelvic pain syndrome (this term includes inter stitial cystitis and chronic prostatitis), vulvodynia, over active bladder, prostatic pain syndrome, pre menstrual syndrome, sexual (including erectile) dysfunction, chronic pelvic pain, fibromyalgia syndrome, chronic fatigue syndrome, migraine, eating disorders, nutri tional intolerances and others 11 . All of these syndromes consider ably overlap with IBS in population studies to a degree that is often beyond what is expected based on the prevalence rates of the individual diseases. Given that many of these conditions are only diagnosed in special ized centres, it has been questioned as to whether some of these conditions -for example, IBS and chronic pelvic pain -are one and the same disease 12 . In addition, most epidemiological studies note the presence of psychiatric comorbidities (such as anxiety, depression, somatization or neuroticism) not only for IBS but also for these IBSassociated diseases. Again, the rates are above the expected levels for IBS and the popu lation prevalence of these symptoms 13 . Thus, the entire disease entity (IBS, functional gastrointestinal disorders and other functional nongastrointestinal dis orders) has been included in the term 'somatic symptom disorder'
Box 1 | IBS definition and subtypes: Rome III criteria
Diagnostic criteria* for irritable bowel syndrome (IBS) include recurrent abdominal pain or discomfort ‡ at least 3 days per month in the past 3 months associated with two or more of the following:
• Improvement with defaecation • Onset associated with a change in the frequency of stool • Onset associated with a change in the form (appearance) of stool *Criteria fulfilled for the past 3 months with symptom onset at least 6 months before diagnosis. ‡ Discomfort means an uncomfortable sensation not described as pain. In pathophysiological research and clinical trials, a pain or discomfort frequency of at least 2 days per week during screening evaluation for subject eligibility. Adapted with permission from REF. 119 , American Gastroenterology Association.
Nature Reviews | Disease Primers
Hard or lumpy stools (%) in the Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM5) 14 and in psychiatric or psychosomatic clinical management 15 . Patients with IBS who were treated by psychiatrists frequently did not receive adequate attention with respect to their gastrointestinal symptoms before the release of DSM5.
Risk factors for IBS
The bestdocumented risk factor for IBS is female sex, which is associated with an odds ratio of 1.67 (95% CI: 1.53-1.82) across many populationbased studies 16 , with explanations varying between sexdifferent health care, consultation behaviour and biological functions (for example, hormonal regulation of gut functions). The incidence of IBS decreases with advancing age (>50 years) 1 , but is similar in children and adolescents compared with adults and does not necessarily trans mit from childhood to adulthood 17 . However, family aggregation has been reported 18 that is driven by genet ics 19 as well as by social learning 20 . BOX 2 lists the per sonal, disease, psychosocial and social factors that have been found to be associated with increased risk of IBS, although some of these factors have only been identi fied in individual studies 21 or have been found to vary between countries and settings.
Post-infectious IBS
Several studies have shown an association between IBS and preceding gastrointestinal infections of bac terial, viral or other origin 22, 23 . The pooled odds ratio is 7.3 (95% CI: 4.7-11.1) for the development of IBS after infectious gastroenteritis 24 , with a median prevalence of ~10% 22 . This association seems to differ with respect to epidemic infectious events that affect many people at the same time and individual infections, such as travel lers' diarrhoea. That is, prevalence data are reported to be higher (15-30%) in epidemic events 22 and lower (5-10%) following travellers' diarrhoea 23 ; these differences are presumably due to different reporting biases in these populations. Thus, a median prevalence of 10% might better reflect the true prevalence of postinfectious IBS than the extreme values reported in individual studies. Risk factors for the development of postinfectious IBS are female sex, younger age, the severity of the initial infection and premorbid psychological conditions [22] [23] [24] . Based on symptoms alone, postinfectious IBS cannot be distinguished from IBS without an infectious origin, but inflammatory biomarkers may. The most valid dis tinction may be a sudden onset that is well remembered by the patient and is associated with fever, bloody stools and a positive laboratory stool test for an infective agent.
Mechanisms/pathophysiology
Although the aetiology of IBS remains largely undeter mined, our understanding of the potential mechanisms involved in gut dysfunction, visceral sensation and symptom generation is rapidly advancing. Growing evidence suggests that, in IBS, the epithelial barrier, gut microbiota, food antigens and bile acids elicit abnormal responses in the key regulators of sensorimotor func tions, including the hypothalamus-pituitary-adrenal (HPA) axis, the immune system, the brain-gut axis and the enteric nervous system (ENS) (FIG. 4) . Accordingly, these factors might have a role as potential biomark ers of disease
. In addition to these putative bio markers, psychological factors ('psychomarkers') such as depression and anxiety, which are known to respond to abdominal symptoms (bottomup), and psychosocial factors ('stress') that influence physiological (intestinal) functions, such as motility and visceral sensitivity (top down), have been acknowledged and will be discussed in more detail.
The epithelial barrier
The epithelial gut lining represents an enormous sur face that is in constant contact with the environment and with billions of bacteria that constantly challenge the intestinal immune system. Increased intestinal per meability is considered an early event in IBS that leads to lowgrade immune cell infiltration of the gut mucosa 25 . Indeed, increased epithelial permeability has been pri marily described in postinfectious IBS in general and in IBSD in particular, although some reports have also shown that IBSC and IBSM might also involve an increase in epithelial permeability 25 . Evidence for the presence of this remodelling in IBS has been provided by electron microscopy, which has detected enlarged spaces between epithelial cells and cytoskeletal condensation in gut biopsies of patients with IBSD 26 . In addition, Ussing chamber experiments, which measure epithe lial membrane properties on colonic mucosal biop sies, have shown excessive passage of macromolecules from the luminal to the basolateral side of gut tissue in biopsies obtained from patients with IBS compared with asymptomatic controls, hence providing the func tional correlate for the described structural epithelial barrier defects 27 . Morphological and functional changes in intestinal permeability are related to abnormal gene and protein expression of tight junction proteins, including a reduc tion in the expression of occludin and zonula occludens protein 1 (REFS 25, 28) . These findings have recently been corroborated by genetic and epigenetic findings in tight junction proteins claudin 1, claudin 2 and cingulin, as outlined below. Tight junction changes are probably the result of both bacterialmediated and proteasome mediated degradation triggered by lowgrade inflamma tion 29 . Accordingly, inflammatory mediators including eicosanoids, histamine and proteases increase intestinal permeability. This may involve the participation of ENS neurons, which may amplify these effects 27, 30 . Increased intestinal permeability has been linked to diarrhoea and pain severity 26 , suggesting that this mech anism might have a role in symptom generation in IBS. Although the exact causes underlying the 'leaky' gut barrier in IBS remain elusive, it has been postulated that numer ous factors could be involved, including genetics, epi genetics, dysbiosis and food allergies 25 . Confocal laser endo microscopy of the duodenal mucosa of patients with IBS after challenge with food to which the patients reported intolerance showed epithelial breaks and increased inter villous spaces, indicative of increased intestinal perme ability. These studies suggest a causative effect of food in the increased epithelial permeability in IBS 31 .
Bile acids
A subset of patients with features compatible with IBSD present with increased levels of total faecal bile acids caused by increased excretion and synthesis of serum C4 (7αhydroxy4cholesten3one; a surrogate for bile acid synthesis), which in turn influences bowel habit by acceler ating colonic transit and inducing diarrhoea and visceral hypersensitivity in IBS [32] [33] [34] . Of note, genes involved in bile acid metabolism and function have been reported to be associated with colonic transit in IBSD, as outlined below.
Immune response
It has been argued that the immune system participates in the pathophysiology of IBS based on the clinical obser vation that infectious gastroenteritis is a strong risk factor for the development of IBS 24 . Additional clinical support comes from the evidence that about onethird of patients with IBD in remission experi ence IBSlike symptoms 35 . These inferential data have been subsequently enriched by quantitative immuno histochemistry data showing increased infiltration of T cells and mast cells in the mucosa of the small and large intestine of some patients with IBS 36 . Two randomized controlled trials (RCTs) 37, 38 in patients with IBS demonstrated that the antiinflammatory agent mesalazine was not superior to placebo in alleviating IBS symptoms, although both studies clearly indicated that subgroups, particularly patients with postinfectious IBS, had sustained symptomatic responses. Thus, these stud ies confirm the hypothesis that immune activation has a considerable role in some patients with IBS. 
IBS-M IBS-C IBS-D IBS-U
Although mucosal immunocyte numbers are not always increased in IBS, there is strong functional and molecular evidence of an increased state of activation of immune cells in about half of patients with IBS 36 . Data from several studies point to the importance of mast cells as key components of inducing and maintaining low grade immune activation in IBS 36 . For instance, higher proportions of mast cells were found in a degranulating state in colonic biopsies from patients with IBS than in control samples, suggesting that increased activation of mast cells is involved in the condition 39 . In addition, biopsy supernatants from patients with IBS contained higher amounts of mast cell mediators, including pro teases and histamine 36 as well as poly unsaturated fatty acid metabolites 40 , than controls. Mucosal immune activation is coupled with altered gene expression of several components of the host mucosal immune response to microbial pathogens (see below), suggesting that the microbiota might contribute to the observed immune activation 36 .
Neuroimmune interactions
Mucosal mediators isolated from biopsy samples from patients with IBS have been extensively studied to identify their effect on bowel physiology and sensory perception in isolated tissues or laboratory animals 41 . Compared with controls, mucosal mediators from patients with IBS evoked higher activation of visceral and somatic pain pathways when applied to intestinal preparations isolated from rodents 42, 43 . Mast cells and enteroendocrine cells have been suggested to partici pate in this abnormal neural signalling, as indicated by the activation of human ENS neurons via mast cell derived histamine, enteroendocrine cellderived sero tonin (also known as 5hydroxytryptamine (5HT)) and proteasedependent mechanisms 30, 42 (FIG. 5) .
Although most of the proteases are secreted by mast cells, some of the serine and cysteine proteases that are present at a higher level in the mucosa or stool of patients with IBS than controls might be of other, prob ably pancreatic or bacterial, origin. In line with these findings, serine proteases in faecal supernatants from individuals with IBSD evoked colonic hypersensitiv ity to distension 44 . By contrast, faecal cysteine protease activity was augmented in some patients with IBSC compared with controls and increased protease activity correlated with abdominal pain and impaired epithe lial permeability 45 . Further work showed the implica tion of serine proteases that act on protease activated nociceptors located on intestinal nerves convey ing pain stimuli to the brain 43 . Importantly, mucosal mediators from patients with IBS and visceral hyper sensitivity -but not from normosensitive patients with IBS -acutely activated spinal nociceptors when given to animal models 46 . In the same model, chronic exposure to soluble mediators from patients with IBSD was shown to sensitize noci ceptive neurons 47 , implying that chronicity is associated with longlasting plasticity alterations.
Attention has been directed to agonists of the tran sient receptor potential cation channels (TRPs), which have been implicated in the pathogenesis of sensory hyperalgesia. Colon tissue samples from patients with IBS have increased levels of specific polyunsaturated fatty acids, which stimulate sensory neurons from mice via the activation of TRP subfamily V member 4 (TRPV4) and generate visceral hypersensitivity 40 . The importance of those visceral afferents that express TRPs in IBS symptomatology is underscored by the finding that peripheral blood mononuclear cell (PBMC) super natants from patients with IBSD cause mechanical hypersensitivity of visceral afferents via tumour necro sis factor (TNF) and TRPA1; this was not observed if control supernatants were used 48 . Recent data support the concept that the chronic release of factors with known effects on nerves in the intestinal milieu might not only have functional effects but could also affect the ENS and sensory fibres in a structural manner. For example, immunohisto chemistry showed a 57.7% and 56.1% increase in mucosal neu rons and neuronal outgrowth, respectively, in patients with IBS compared with healthy controls 49 . Indeed, . The different components should be viewed as layers of complexity: the IBS subtypes are part of the group of functional bowel disorders, these are part of all kinds of functional disorders and these again are part of a 'layer' of psychiatric disorders. GERD, gastroesophageal reflux disease; IBS-C, IBS with constipation; IBS-D, IBS with diarrhoea; IBS-M, mixed-type IBS; IBS-U, unsubtyped IBS; PMS, premenstrual syndrome.
the intestinal mucosa of patients with IBS contains increased levels of nerve growth factor (NGF), primar ily in mucosal mast cells. Experimentally, the effect of NGF was demonstrated in primary cell cultures of the rat myenteric plexus and the neuroblastoma cell line SHSY5Y, which showed an increase in neurite growth, and protein and mRNA expression of growthassociated protein 43 (GAP43; also known as neuromodulin) -a key neuronal growth protein -following exposure to supernatant obtained from mucosal biopsies of patients with IBS 49 .
Microbiota
The gastrointestinal microbiota is a diverse and numer ous ecosystem that inhabits the entire gastrointestinal tract and has a systemic influence on our health. Owing to its enormous complexity and high interindividual variability, the microbiota is still in large part undefined regarding the scope of its contribution to human physio logy and tolerable compositional variations under which normal functions are preserved 50 . The evidence for an involvement of altered gut microbiota composition in IBS pathophysiology has been accumulating (BOX 4) , but the aetiological role remains uncertain. The most prominent markers of IBS are derived from uncultured bacteria. Two groups of uncultured Clostridiales are significantly depleted in IBS 51, 52 , and bacteria related to Ruminococcus torques (a species belonging to the Lachnospiraceae) are profoundly enriched in patients with IBS 51, 53, 54 and levels positively correlate with bowel symptoms 51, 52, 55 . In addition, increased Firmicutes to Bacteroidetes ratios have been observed at the phylum level, at least in a subset of patients 51 (for a recent review see REF. 56 ). Given the provided evidence, the dysbio sis of microbiota in IBS has been acknowledged by the Rome Foundation Working Team 57 as a plausible contributing factor to the disorder. Experiments with animal mod els have shown that colonization of germfree animals with microbiota from patients with IBS can induce visceral hypersensitivity 58 , impair intestinal perme ability and alter gastro intestinal transit time 59 -indi cating the importance and the possible aetiological role of the microbiota in IBS.
Although diet changes have an effect on the abun dance of particular microbial groups, the microbiotic signature (in terms of present species) is very stable 60 . To observe a profound effect, the dietary change has to be dramatic (for example, vegans switching to high fat and highprotein diets 61 ). Dietary interventions (such as low dietary content of fermentable oligo saccharides, disacchar ides, monosaccharides and poly ols (FODMAPs; BOX 5) , or the addition of sweeten ers (fructooligosaccharides) or fibre (psyllium)) can improve symptoms of some but not all patients with IBS. Future studies should evaluate the relevance of these microbial groups for IBS and could contribute to a better understanding of the role of the microbiota in the pathophysiology of IBS that is currently acknowledged for the following contexts.
Fermentation of non-digestible foods. An important role of the microbiota is degradation of non digestible dietary components 62 . It is generally accepted that fermentation of carbohydrates is desirable because of the beneficial effects of the main fermentation products -shortchain fatty acids (SCFAs) -including energy supply to gastro intestinal epithelial cells, a decrease in inflammation and improvement in gut barrier function 63 . However, in patients with IBS, the presence of the resistant carbohydrates FODMAPs can provoke IBS symptoms 64 . This might be a result of over production or underproduction of relevant metabolites owing to the disturbed microbiotic balance, for example, due to an increased abundance of gas producing and decreased abundance of gas utilizing micro organisms. The quantity and composition of SCFAs in the gut differs between patients with IBS and healthy con trols, although the available data are not always in agreement 65, 66 . Moreover, the production of microbial SCFAs stimulates regulatory T cell differentiation and affects the balance between proinflammatory and anti inflammatory mechanisms 67 , suggesting that inade quate levels of SCFAs could provoke lowgrade intestinal inflammation as observed in patients with IBS 68, 69 . Finally, studies of microbiota show that the abundance of several SCFAproducing bacteria -including Roseburia, Blautia and Veillonella 70 -is significantly increased compared with the levels of these bacteria in healthy controls, providing a potential mechanistic basis for the development of IBS symptoms.
Other carbohydrateutilizing gastrointestinal bac teria -namely, Dorea spp. -show significant increases in abundance in patients with IBS 51 ; these are the main gasproducing bacteria in the human gastrointestinal tract 71 . The overproduction of gas is associated with IBS 72 and this phenomenon could underlie flatulence and abdominal pain. The excessive production of gas can also cause faster colonic transit in patients with IBSD, as the colons of these patients are more sensitive to increased intestinal volume than healthy controls 73 . Intestinal gases are efficiently removed by methano genic archaea 74 , which seem to be depleted in patients with IBS 51, 52 and are negatively correlated with the pres ence of loose stools 52 . However, a significant increase in the abundance of this microbial group is character istic of patients with slow transit and constipation 75 , whereas the degree of the methanogenic activity could be correlated with the severity of constipation in those with IBSC 76 . Another potential pathway for microbiotic involve ment in IBS is protein degradation. The luminal con tents of patients with IBS contain increased levels of proteases 30 , which could be due to the increased secretion of endogenous and microbial proteases in response to proteinrich nutrition (typical of western diets), but could also be due to insufficient endo genous protease degradation by the disturbed gastrointestinal microbial community 77 . Serine protease inhibitors are produced by many bacteria, including bifidobacteria 78 , and their activity could prevent the excessive proteo lytic activity of intestinal content in IBS. The depletion of bifido bacteria has been noted in both faecal and mucosal samples of patients with IBS 51, 79 , suggesting an important role for this bacterial genera in IBS. The fermentation of proteins generates numerous health compromising substances 80 . Among these, hydrogen sulfide is a relevant toxin that impairs epithelial metabo lism 81 and can be further converted to tetrathionate, which stimulates the growth of tetrathionateutilizing pathogens from Gammaproteobacteria 82, 83 . The abun dance of several Gammaproteobacteria significantly corre lates with bowel symptoms in patients with IBS 51, 52 , and also with the levels of the inflammatory markers inter leukin 6 (IL6) and IL8 (REF. 51 ) that are typically increased in IBS 54 .
Microbiota and 5-HT.
5HT is an important metabolite that, among other functions, regulates gastrointestinal motility; disturbed levels of 5HT seem to be relevant for IBS pathology 84 . As much as 90% of 5HT is pro duced in enteroendocrine cells present in the gastro intestinal tract, and it has been recently shown that intestinal bacteria are needed for the stimulation of 5HT synthesis. Attempts to identify microorganisms that are capable of 5HT synthesis have shown that, in contrast to Bacteroides spp. and altered Schaedler flora (a community of eight bacterial strains), only specific sporeforming commensal bacteria have this feature. The majority of these sporeforming bacteria belong has not yet been completely elucidated, various factors have a role, including composition of the gut microbiota, intestinal permeability, immune cell reactivity and sensitivity of the enteric nervous system, the brain-gut axis (spinal, vagal or pelvic pathways) or the brain. The figure highlights those mediators that are probably involved in IBS pathology. The plus symbols indicate whether a mediator activates or inhibits its target cell; those in parentheses denote actions established in animal models and those without parentheses are effects demonstrated in humans (human tissue). 5-HT, 5-hydroxytryptamine (also known as serotonin); CGRP, calcitonin gene-related peptide; GDNF, glial cell-derived neurotrophic factor; IL, interleukin; PAR2, proteinase-activated receptor 2; TNF, tumour necrosis factor.
to the Clostridales class within the Firmicutes phy lum. Two recent comprehensive studies 51, 85 revealed an increase of the Firmicutes phylum members on the account of the Bacteroidetes members in IBS. Given that the Clostridiales class within the Firmicutes phylum are the most diverse and the most abundant group of the microbiota 70 , it is not clear if the observed feature of the IBS microbiota is associated with 5HTmediated pathophysiology, but this possible link should certainly be further investigated.
Brain and behaviour IBS is narrowly defined by recurrent abdominal pain and discomfort associated with altered bowel habits in the absence of an organic origin and/or explanation of symptoms. However, given that IBS is nearly always associated with increased anxiety and patients often show comorbidities with other chronic pain and psychi atric conditions, a more widespread dysregulation of the nervous and immune systems is probably implicated 86 . The brain, the gut and its microbiota and the immune system show reciprocal associations in health and dis ease. On the one hand, the brain, via the autonomic nervous system and the HPA axis, can influence intes tinal motility and fluid secretion 87 , intestinal epithelial permeability 25, 88, 89 , immune function 90 and gut micro bial composition 91 , all of which have been reported to be dysregulated in IBS. On the other hand, several of these peripheral alterations can influence brain structure and function either developmentally or in response to acute perturbations, setting up circular regulatory loops between the gut and the brain 92 .
In addition to its role in the bidirectional communi cations with the gut, the brain plays an essential part in assessing the salience of received or expected intero ceptive (sensory) information 93 , determining how much of this information is amplified or tuned down, to what degree it is modulated by affect 94 and how much of this interoceptive information from the gut is consciously perceived (visceral sensitivity). One of the beststudied behavioural aspects of IBSrelated central processing of gutrelated information involves a coping strategy referred to as catastrophizing, a term that refers to a bias towards prediction of a high likelihood of worst outcomes 95 . This measure strongly correlates with the severity of pain symptoms and is a primary treatment target in cognitive-behavioural therapy.
Multimodal brain imaging has made it possible to identify differences in functional (evoked and resting state) and structural (grey matter and white matter tracts) aspects of specific brain networks that provide a neurobiological substrate for previously observed affective and cognitive features of IBS (reviewed in REFS 92, 96) (FIG. 6) . These networks include the salience, attention, sensorimotor and emotional arousal net works. Profound sexrelated differences in these networks have also been identified in both healthy individuals and patients with IBS (reviewed in REF. 96 ). Crosssectional correlations of brain networks with sev eral clinical and nonbrain biological parameters show a relationship between some of these brain signatures with IBS symptom severity and duration, a history of early adverse life events 93 , gut metabolite and microbial composition 97 , gene expression profiles in PBMCs 98 and gene polymorphisms 99 . On the basis of these neuro biological findings, a comprehensive IBS pathophysio logical model can be formulated (FIG. 6) , which includes alterations in the appraisal of and selective attention to interoceptive signals (salience and attentional network), central sensory processing of interoceptive information (sensorimotor network) and engagement of emotional arousal associated with experience and expectation of Although these findings have identified disease relevant brain alterations in patients with IBS, mech anistic and longitudinal studies are required to determine the causality between these factors. For example, are central sensorimotor alterations a conse quence of increased signals from the gut, are they the consequence of dorsal horn sensitization by increased descending pain facilitating signals or are they a genet ically determined trait that predisposes individuals to IBS and might be present in asymptomatic relatives 100 
?
The correlation of gut microbial signatures and PBMC expression profiles with structural alterations in the Figure 5 | Neuroimmune interactions in the gut. An intimate anatomical and functional association between enteric neurons, terminals from extrinsic nerves and cells of the enteric immune system is the basis for neuroimmune interactions in the gut wall. Functional signalling between nerves and immune cells mostly happens in the epithelial and sub mucosal layers where there is a high density of immune cells -in particular, T lymphocytes, mast cells and macrophages. The neuroimmune interactions are bidirectional. Enteric neurons, extrinsic nerves and glial cells respond to cytokines and mast cell mediators. Some patients with irritable bowel syndrome (IBS) have circulating autoantibodies against neuronal structures and antibodies that are generated as a response to antigen exposure from the lumen. Neurons can respond directly to antibodies through direct activation of channels or receptors. They also respond to antigens through pathways involving neuronal Toll-like receptor 3 (TLR3), TLR4 and TLR7. Direct signalling between microbiota and the host involves activation of neurons through polysaccharide A. These direct effects of luminal factors are very likely to be outnumbered by signalling between epithelial (in particular, enteroendocrine cells), immune and nerve cells. Neurons also express receptors for adenosine and ATP; both molecules are released in the gut wall under inflammatory or stress conditions. Reciprocally, nerves release factors that affect epithelial or immune cells. The best-documented effect is the activation of mast cells through the release of calcitonin gene-related peptide (CGRP) from extrinsic visceral afferents or enteric neurons. Conversely, acetylcholine (ACh) inhibits the activation of macrophages. Neurogenic inflammation, which is sometimes observed in animal models, is probably caused by the release of CGRP and substance P from extrinsic fibres followed by permeabilization of blood vessels. In addition, adipocytes in the lamina propria nestle against nerve fibres, and release of their pro-inflammatory mediators modulates nerve activity. The plus and minus symbols indicate whether a mediator activates or inhibits its target cell; those in parentheses denote actions established in animal models and those without parentheses are effects demonstrated in humans (human tissue). 5-HT, 5-hydroxytryptamine (also known as serotonin); CCK, cholecystokinin; CRF, corticotropin-releasing factor; IL-10, interleukin 10; NGF, nerve growth factor; PUFA, polyunsaturated fatty acid; TRP, transient receptor potential cation channel.
sensorimotor network suggests a possible role of these peripheral factors in influencing the brain. Similarly, are the altered salience and attention network alterations a secondary response to the chronically increased per ception of visceral signals or are they a primary abnor mality that is responsible for the generation of aberrant endogenous pain modulation, as well as emotional and autonomic nervous system responses? Future studies will need to address the question of whether these brain signatures differ between subgroups of patients with IBS, such as male and female patients, patients with a history of early adversity, patients with different durations of symptoms and patients with postinfectious IBS.
Genetic and epigenetic data
The latest genetic and epigenetic findings support cur rent models of IBS pathogenesis that suggest disturbed intestinal barrier function, immune response and neuro nal signal transduction 101 (FIG. 6) . The data even point towards potential diagnostic biomarkers or therapeutic options
. For example, silencing the microRNA29 (mir-29) family or amplifying mir-199a expression might have important therapeutic implications for selected patients with IBS and symptoms caused by increased intestinal permeability or hypersensitivity 102, 103 . Genetic data. Genetic studies to date range from fam ily and twin studies to candidate gene approaches and, more recently, genomewide association studies (GWAS). Regardless of enlarged sample sizes, increased statistical power and metaanalyses, genetic variants associated with IBS are still scarce and/or have not been replicated in independent cohorts. A recent paper summar izes all currently available genetic data that have been replicated 101 . Polymorphisms or variants in several genes have been found to be associated with IBS. Genes encoding proteins involved in homeostasis of epithelial barrier function, such as cadherin 1 (CDH1) and cell division cycle 42 (CDC42), the immune system, such as IL6, IL10, TNF and TNF superfamily member 15 (TNFSF15; encod ing cytokines and neuronal signal transduction) and others (such as neurexophilin 1 (NXPH1) and sodium voltagegated channel αsubunit 5 (SCN5A)) have been replicated in several studies 101 . In 2014, a small pilot study reported an association between IBS and a locus on chro mosome 10 (containing the protocadherin 15 (PCDH15) gene) in a discovery sample from Australia that could not be replicated in additional cohorts from Sweden and the United States 104 . Mutations in the following genes encod ing proteins involved in the serotonergic system have also been shown to be associated with IBS: solute carrier fam ily 6 member 4 (SLC6A4; also known as 5HTTLPR or SERT), 5HT receptor 3A (HTR3A)
105
. Furthermore, a functional polymorphism in HTR3A could be associated with altered amygdala responsiveness, anxiety and increased symptom score in IBS 106 . These findings underline the effect of polymorphic serotonergic and other genes in modulating gut derived brain response in areas that process visceral perception and integrate autonomic con trol, salience and somatosensory and emotional central networks (FIG. 6) .
Variants of genes encoding proteins that are involved in bile acid synthesis regulation (the Klothoβ (KLB) gene, the fibroblast growth factor receptor 4 (FGFR4) gene and the G proteincoupled bile acid receptor 1 (GPBAR1) gene) are associated with accelerated colonic transit in patients with IBSD 107, 108 . These variants also correlate with the colonic transit response to cheno deoxycholic acid (a bile acid used to treat constipation) in IBSC 109 and to colesevelam (a bile acid sequestrant used to treat diarrhoea) in patients with IBSD 110, 111 . Finally, a locus at 7p22.1 in which the genes KDEL endoplasmic reticulum protein retention receptor 2 (KDELR2) and GRID2interacting protein (GRID2IP) localize was significantly associated with IBS risk in the index GWAS (a large twin discovery sample from Sweden) and all replication cohorts in Europe, the United States and Australia
112
. However, the under lying molecular cause for this association finding has not been elucidated.
Epigenetic data. Even less insight into the role of epi genetics in IBS pathology is available compared to the genetic implications. To date, only a few miRNA studies have been performed. These studies reported on the differential expression profiles of miR29a, miR29b, miR103, miR16, miR125b and miR199a in the intes tinal mucosa of patients with IBSD. Upregulation of miR29a and miR29b was reported to accompany downregulation of the target genes encoding glu tamine synthetase (GLUL) 102 , claudin 1 (CLDN1) and NFκBrepressing factor (NKRF); CLDN1 and NKRF correlated with increased gut permeability 103 . In addi tion, decreased expression of miR103, miR16 and miR125b correlated with the upregulation of the tar get genes encoding the tight junction proteins claudin 2 (CLDN2) and cingulin (CGN) 113 . In turn, a diminished miR199 level correlated with an upregulation of TRPV1 and increased visceral sensitivity 114 . Moreover, variants residing in miRNA target regions of the 5HT receptor genes HTR3E and HTR4B -namely, c.*76G>A and c.*61T>C -were found to be associated with IBSD. Both variants were reported to impair miRNA regula tion and to lead to disturbed expression regulation of miR510 and miR16, respectively 115, 116 . One pilot study further indicated increased levels of circulating miR150 and miR3423p in the blood of patients with IBS 117 . Of note, miR150 has been described to be associated with IBD and pain, whereas miR3423p has been predicted to target genes that are relevant for pain signalling, colonic motility and smooth muscle function 118 .
Diagnosis, screening and prevention
The diagnosis of IBS relies on the patient fulfilling diagnostic criteria for IBS 119 in conjunction with nor mal results on a limited number of additional tests and investigations used to rule out other diagnoses with reasonable certainty (FIG. 7) . Although a substantial proportion of clinicians 120 prefer a process of thorough exclusion of other diseases, the current recommendation is to base diagnosis on symptoms 119 . There is currently no valid biomarker for IBS 121 . The choice of the tests or investigations deemed necessary to rule out other con ditions varies depending on the clinical situation and the symptom profile of the patient. In the majority of cases with a typical clinical history compatible with IBS, only a limited number of laboratory tests are recom mended without any need to perform invasive investi gations. Screening for IBS risk and for prevention of IBS develop ment is currently not applicable, given the hetero geneity of the disease and the multiplicity of putative pathophysiological mechanisms.
Diagnostic criteria
As individual symptoms have poor sensitivity and speci ficity to diagnose IBS, diagnostic criteria incorporating a combination of symptoms have been developed, similar to the DSM system within psychiatry. The first attempt was the socalled Manning criteria, published in 1978 (REF. 122 ). In this publication, several symptoms were shown to be more common in patients with IBS than in patients with another organic gastrointestinal disease. By combining these symptoms, IBS could be discrimin ated from other organic gastrointestinal diseases. The experience from the Manning criteria was then used to develop the Rome Foundation criteria, with three differ ent versions over the past 15 years (Rome I, II and III); the latest criteria, the Rome III criteria, was published in 2006 (REFS 119, 123, 124) . The updated Rome IV criteria are expected in May 2016. The sensitivity and specificity of the Rome criteria have been found to be 69-96% and 72-85%, respectively, in different studies, but a problem with these studies is how to define the gold standard for an IBS diagnosis 121 .
The common feature in all of these diagnostic cri teria is abdominal pain and/or discomfort associated with abnormal bowel habit (diarrhoea (loose and fre quent stools), constipation (hard and infrequent stools) or alternating constipation and diarrhoea). All of these criteria require a certain duration and frequency of the symptoms to fulfil the diagnostic criteria for IBS; that is, the symptoms should be chronic and recurring. Thus, the practical clinical use of the diagnostic criteria for IBS involves demonstrating through the clinical his tory the presence of a combination of these symptoms for ≥3 days per month in the past 3 months, with symptom onset ≥6 months before the diagnosis (Rome III cri teria). However, it should be noted that patients with some organic gastrointestinal disease also meet these diagnos tic criteria 125 and, as such, the sensitivity and specificity of these criteria is suboptimal to distinguish the different disease entities 125, 126 .
Clinical features
Besides the symptoms included in the diagnostic criteria, there are other clinical features that support a diagnosis of IBS, even though none of them is mandatory for an IBS diagnosis. One recent study found that variations in stool consistency and frequency or an unpredictable bowel pattern ('irregularly irregular') could be used to discriminate IBSD adequately from organic gastro intestinal disease 127 . Moreover, abnormal stool frequency (>3 bowel movements per day or <3 bowel move ments per week), excessive straining during defaeca tion, urgency (having to rush to the toilet), feelings of incomplete evacuation and mucus with bowel move ments support an IBS diagnosis, but are nonspecific 124 .
Box 5 | FODMAPs and a low FODMAP diet*
FODMAPs stands for fermentable oligosaccharides (fructans present in wheat, rye, onion and garlic chicory; and galactans present in legumes and beans), disaccharides (lactose present in milk and milk products), monosaccharides (fructose present in artificial sweeteners) and polyols (sugar alcohols present in apples, pears, stone fruit, cauliflower, mushrooms and sweeteners). A low FODMAP diet may include reasonable amounts of: • Vegetables: bamboo shoots, cucumber, carrot, corn, aubergine (eggplant), lettuce, leafy greens, pumpkin, potato, squash, yam, tomato and courgette (zucchini), among others • Fruits: banana, cantaloupe, grapes, grapefruit, kiwifruit, kumquat, lemon, lime, mandarin, orange, passion fruit, pawpaw, pineapple, rhubarb and tangerine, among others • Protein: beef, chicken, canned tuna, egg, egg whites, fish, lamb, pork, shellfish, turkey, cold cuts, nuts and seeds, among others • Dairy and non-dairy alternatives: lactose-free milk, cream cheese, hard cheeses (cheddar, parmesan and Swiss), mozzarella and sherbet (almond milk, rice milk and rice-milk ice-cream), among others • Grains: wheat-free grains or wheat-free flours and products made with these (for example, bagels, breads, crackers, noodles, pancakes, pastas, pretzels and waffles), corn flakes, cream of rice, grits, oats, quinoa and rice, among others The same is true for postprandial worsen ing or exacer bation of symptoms, which is common in IBS 128 , but is also observed in other gastrointestinal diseases. The presence of other functional gastro intestinal diagnoses (such as functional dyspepsia) 129 , as well as reporting numerous functional nongastrointestinal symptoms and syndromes (such as chronic fatigue, fibromyalgia, urogynaecological symptoms, muscle and joint pain and sleep disturbances) 11, 130 and psychological comor bidity (such as anxiety and depression) 131 , are all common and support an IBS diagnosis.
Physical examination
A physical examination should be part of the evalu ation to reassure patients and also to help exclude another organic cause of the symptoms. Admittedly, an abdominal examination, which is part of the routine examin ation, rarely discloses a specific diagnosis (that is, abdominal tenderness is present in various diseases), but the absence of objective findings on a physical examin ation has been found to support a diagnosis of IBS 132 . A digital rectal examination is an important part of the physical examination and a useful tool to identify patients with dyssynergic defaecation, which is important to exclude in patients with constipation 133, 134 as well as to exclude rectal cancer. Perianal inspection should also be part of the examination to rule out perianal fistulas and other relevant anal pathology.
Laboratory tests
From the existing literature, it is not obvious which labora tory test to recommend in the diagnostic workup of patients with IBS symptoms. Only serological tests for coeliac disease seem to be more likely to be abnormal in patients with symptoms compatible with IBS than in the general population 135 , even though a large multi centre trial failed to confirm this 136 . However, few studies have systematically evaluated the usefulness of laboratory tests in patients with potential IBS. A recent systematic review demonstrated that Creactive protein (CRP) levels of ≤0.5 mg per dl or faecal calprotectin levels of ≤40 μg per g essentially exclude IBD in patients with IBS symptoms 137 . On the basis of the existing literature, it seems reasonable to perform a complete blood count and CRP measure ment, as these are inexpensive and can be used to reassure the healthcare provider and the patient. A thyroid profile can be included if the clinical suspicion of thyroid disease is high, a serological test for coeliac disease can be recom mended in patients with nonconstipated IBS and -if there is suspicion of an inflammatory process -a faecal calprotectin measurement can be added. Stool analyses to detect gastrointestinal infections can be considered if diarrhoea is predominant and difficult to treat, especially in regions where infectious diarrhoea is common 138 . As stated previously, there is currently no valid diagnostic biomarker, even though preliminary data have suggested that certain biomarkers or biomarker assays (BOX 3) for clinical use might prove to be valid following further scientific investigation 139, 140 .
Alarm features
Alarm features for IBS are symptoms that should raise the clinical concern of another gastrointestinal disease rather than IBS. Whether the use of alarm features (BOX 6) improves the performance of diagnostic criteria for IBS is not totally clear 125, 141 . However, from a clinical point of view, it seems reasonable to use these to select patients for further diagnostic testing, even though these may be . Various pathways might be affected in specific subgroups of patients with IBS: epithelial barrier (permeability), immune function, impaired bile acid metabolism and function, neuronal processing and signal transduction via spinal afferents from the periphery to the central nervous system in addition to the bidirectional crosstalk via the brain-gut axis, presumably contributing to psychological conditions such as anxiety, depression and somatization. Brain networks that have been associated with structural and functional alteration in IBS are depicted. ADRA, adrenoceptor-α; aINS, anterior insula; aMCC, anterior midcingulate cortex; CDC42, cell division cycle 42; CDH1, cadherin 1; CGN, cingulin; CLDN, claudin; COMT, catechol-O-methyltransferase; CRHR1, corticotropin-releasing hormone receptor 1; FGFR4, fibroblast growth factor receptor 4; GLUL, glutamate-ammonia ligase (also known as glutamine synthetase); GPBAR1, G protein-coupled bile acid receptor 1; GRID2IP, GRID2-interacting protein; HPA, hypothalamus-pituitary-adrenal; HTR, 5-hydroxytryptamine receptor; hypo, hypothalamus; IL, interleukin; KLB, Klotho-β; LCC, locus coeruleus complex; mir, microRNA; mPFC, medial prefrontal cortex; NKRF, nuclear factor-κB-repressing factor; NR3C1, nuclear receptor subfamily 3 group C member 1; NTS, solitary nucleus; OFC, orbitofrontal cortex; PAG, periaqueductal grey; PGR, progesterone receptor; SCN5A, sodium voltage-gated channel α-subunit 5; sgACC, subgenual anterior cingulate cortex; SLC6A4, solute carrier family 6 member 4; TNF, tumour necrosis factor; TNFSF15, TNF superfamily member 15; TRPV1, transient receptor potential cation channel subfamily V member 1. . Alarm symptoms can necessitate fur ther investigations to rule out another gastrointestinal disease before an IBS diagnosis can be recommended. Moreover, the predominance of diarrhoea, especially when watery and frequent, should alert the clinician to consider alternative diagnoses 143 .
Invasive investigations
In the majority of patients with symptoms compatible with IBS and normal routine laboratory tests but without alarm features 144 , no additional invasive investigations are needed and, importantly, performing investigations does not seem to improve patient satisfaction or QOL 145, 146 . Colonoscopy should be performed when alarm fea tures prompt an investigation and when there is suspicion of an inflammatory condition in the gastrointestinal tract based on history or laboratory parameters (increased CRP or faecal calprotectin levels) 137 , or based on the indi cations for colorectal cancer screening in countries with population screening programmes 147, 148 . When the patient complains of watery diarrhoea as the predominant symptom, a colonoscopy with biopsies should also be considered to rule out microscopic colitis, especially in women >50 years of age 143, 149 . Moreover, bile acidinduced diarrhoea has recently been found to be a very important differential diagnosis in patients with IBS symptoms with frequent, loose stools 32, 33 , and a diagnos tic test should be considered (75homocholic acid taurine ( 75 SeHCAT) test or serum C4 levels) 150 . Unfortunately, these tests are not available in all centres, therefore a therapeutic trial with a bile acidbinding agent is often used as an indirect, but far from perfect, assessment of bile acidinduced diarrhoea.
Carbohydrate malabsorption is another differential diagnosis in patients with IBSD [151] [152] [153] , and lactose or fructose hydrogen breath tests can be considered 154, 155 , but a trial period with dietary exclusion of the suspected carbohydrate for several weeks is often used instead.
If coeliac disease is suspected, based on a positive serological test or the clinical history, an upper gastro intestinal endoscopy with duodenal biopsies should be performed. Small intestinal bacterial overgrowth has been proposed to be common in IBS, but its preva lence and clinical importance is uncertain, therefore routine clinical testing for this cannot be advocated 156, 157 , especially as valid tests with adequate sensitivity and specificity are lacking.
Management
Only a fraction of patients with IBSlike symptoms (~50%) seek medical care 158 . Most of these patients will initially consult primary care physicians for their symptoms, and the factors that drive this consultation are symptom severity, especially pain, the occurrence of alarm symptoms (BOX 6) and concerns that symp toms might indicate an underlying severe disease -for example, cancer 159 . Therefore, in many cases, gastro intestinal specialist care is needed to exclude diseases that can mimic IBS symptoms -for example, by endoscopy. Once a positive diagnosis of IBS has been established, clinical management can be carried out as well by primary care physicians and at substantially lower costs 160 . Management of IBS involves an integrated approach, including the establishment of an effective patientprovider relationship, education, reassurance, diet ary alterations, pharmacotherapy and behavioural and psychological treatment 161 . Owing to the fact that ~50-70% of patients with IBS report additional somatic and psychological symptoms when they are asked 161, 162 , a steppedcare approach including aspects of cogni tive and interpersonal therapy is most appropriate 15 . The initial treatment strategy should be based on pre dominant symptoms and includes antispasmodics for abdominal pain, antidiarrhoeals for IBSD and lax atives for IBSC, whereas nutritional interventions and psychotherapy can be used in all subtypes.
Nutrition
Food ingestion is one of the most commonly reported factors that results in the exacerbation of symptoms among patients with IBS 163, 164 . Postprandial symp toms per se and fear of their occurrence (anticipatory anxiety) contribute profoundly to reduced QOL in IBS 128 . Up until recently, foodrelated symptoms had received scant attention from clinical scientists, leav ing patients to find their own way through the plethora of usually nonvalidated and untested diagnostic tests and diet ary regimens, which could result in clinically relevant nutritional deficits 165 . It has become evident that food intolerance (a physio logical reaction to food allergens that is not associated with an immune response), and not classical IgE mediated food allergy (which involves activation of the immune system), is the major mechanism responsible for symptomatic responses to certain foods 165 . This is not to say that immune responses to food or food compo nents are irrelevant for IBS. For example, one study demonstrated that exposure of the small intestine to cer tain food antigens led to subtle ultra structural changes in the duodenal mucosa of patients with IBS, but not in controls 31 . Another study also reported local immune responses to gluten among a group of noncoeliac patients with IBS 166 . Taken together, these observations leave the door open to the possibility that at least some patients with IBS may mount an, as yet to be defined, immunological response to certain dietary components, a response that seems to be confined to the mucosal immune system.
How does one explain foodrelated symptoms in IBS? Given the primacy of food ingestion as a stimulus to most gastrointestinal functions, postprandial pain and rectal urgency in IBS could simply reflect an exaggeration of a normal physiological phenomenon. Exaggerated motor responses to food and, especially to lipids, have also been demonstrated in the small intestine in IBS 167 . Furthermore, tryptophan, the 5HT precursor, and related compounds present in some foods could modu late psychological comorbidities and gastro intestinal symptoms in IBS 168 . Foodrelated symptoms could also be mediated through interactions between our diet, the products of digestion and the gut microbiota. Products of bacterial metabolism, such as deconjugated bile salts, SCFAs and gases, could exert potent effects on colonic physiology and thereby induce symptoms.
Although patients with IBS readily incriminate speci fic food items as those that are especially likely to precipi tate symptoms, only 11-27% of those are correctly identified when confirmed in formal, blinded food chal lenge studies 169 . The limitations of dietary surveys and the poor reproducibility of reported food intolerances notwithstanding, some food items are reported as being more problematic: wheat, fruit and vegetables 170 . Current enthusiasm for diets low in FODMAPs is consistent with these observations. Fibre and fibrebased supplements accelerate colon transit, increase stool bulk and facilitate its passage, resulting in an increase in stool frequency. These effects translate into clinically meaningful benefits for people with chronic constipation and IBSC. Indeed, fibre and products based on synthetic fibrelike sub stances became a cornerstone in the management of IBS. However, RCTs found that not all patients gained relief and some even complained of exacer bation of their symptoms (including pain, bloating and distension). Recent meta analyses and systematic reviews have shed some light on this issue by showing that fibres are heterogeneous and the consumption of soluble fibres such as psyllium, calcium polycarbophil and ispaghula bring symptomatic benefits, whereas insoluble fibres, represented by bran, are ineffective in patients with IBS 169 . Interest in the use of low FODMAP diets (BOX 5) in patients with IBS is increasing. RCTs have confirmed some beneficial effects of low FODMAP diets on IBS symptoms 171 , but they were not superior to conven tional diet ary advice when directly compared 172 . There are some limitations; studies to date have been small and, as has been the case with many studies of dietary interventions in IBS, suffer from some method ological limitations 173 . Furthermore, low FODMAP diets are complex, may require supervision by a qualified diet ician and involve the elimination of many food items commonly regarded as components of a 'healthy' diet. Some initial investigations suggest that the low FODMAP diet may suppress the growth of bacterial species commonly regarded as important components of healthy micro biota, such as bifidobacteria 174 . Included in the FODMAP category are some molecules, such as lactose, fructose and sorbitol; some patients with IBS may benefit from the removal of one of these substances alone 175 . Predicting responders is difficult, as commonly used challenge tests, such as the lactose or fructose breath hydrogen test, do not seem to be of value 175, 176 . The concept of 'noncoeliac gluten sensitivity' has been advanced to explain instances of IBStype symp toms that develop in individuals who do not satisfy diag nostic criteria for the diagnosis of coeliac disease (that is, positive serology and appropriate changes in small intestinal morphology) 177 . This remains an unsettled and contentious issue with some studies reporting that, when tested in a blinded manner, gluten did induce the usual IBS symptoms in some patients with IBS 178 . Others argue that gluten contributes little to IBS symp tomatology, but that fructans (FODMAPs contained in wheat), and not gluten, are the culprits of wheat related problems. Results of clinical trials assessing the role of gluten exposure in IBS pathology have therefore, not surprisingly, yielded mixed results 179, 180 . Although gluten free diets are currently enjoying consider able popularity among patients with IBS and the population at large in the United States, the rationale for gluten exclusion in IBS has yet to be firmly established.
Patients with IBS commonly consume any one or combinations of a wide variety of dietary supplements ranging from vitamins to 'digestive enzymes' , anti oxidants and essential oils. Few, if any, of these have been subjected to rigorous study. Prebiotics (non digestible food ingredients that beneficially affect the host by selectively stimulating the growth and activity of one species or a limited number of species of bac teria in the colon) and probiotics (live microbial food ingredients that alter the microflora and confer health benefit) have also been used for decades in IBS in the absence of supportive data. Prebiotics and probiotics are now subjected to morerigorous studies, as they might 
(+) (-) contribute to altered microbiota in IBS 181, 182 . Although these studies must be interpreted with care, a recent metaanalysis does suggest efficacy for probiotics (as a category) in IBS 183 . However, highquality RCTs remain few in number and available data provide scant infor mation to assist the consumer in choosing a particular product to alleviate symptoms 184 or to make a recom mendation on pre biotics or synbiotics (a combination of a prebiotic and a probiotic) in IBS 185 .
Drug therapy
Broadly speaking, the current therapeutic armamentar ium in IBS aims to alter predominant problematic bowel habits and/or visceral pain. However, an emerging area is manipulation of the gastrointestinal microbiota.
Antispasmodic drugs. Pain in IBS is mediated through central and peripheral mechanisms, and is in part the result of smooth muscle spasms. The mode of action of antispasmodic drugs is probably their ability to antago nize the binding of acetylcholine to the muscar inic receptor at the neuromuscular junction, with smooth muscle relaxation as a consequence 186 . Some studies have demonstrated a beneficial effect of otilonium bro mide and hyoscine over placebo, with a number needed to treat (NNT) of four patients 187 . An adverse effect of antimuscarinic agents is constipation because of their strong inhibition of intra luminal fluid secretion 186 . Accordingly, these drugs are best used in patients with out constipation and should be taken 20 minutes before meals to ease postprandial symptoms. Peppermint oil, which also inhibits smooth muscle contraction albeit by calcium channel blockade, is beneficial in reducing IBS symptoms 188 . A recent RCT in patients with IBSD and IBSM demonstrated that a novel formulation of pepper mint oil, designed to cause a sustained release within the small bowel, was superior to placebo in causing a reduction in total symptoms 189 .
Low-dose antidepressants. Antidepressants, such as tricyclic antidepressants (TCAs) or selective sero tonin reuptake inhibitors (SSRIs), are recommended by existing guidelines for the treatment of pain in patients who are refractory to antispasmodics and dietary alterations 190 . However, these drugs are not licensed anywhere in the world for the treatment of patients with IBS, and their use is offlabel. Given the lack of licensed indication, the rationale for using such drugs should be discussed in detail with patients. The exact analgesic mechanism of action of lowdose anti depressants is incompletely understood but is considered to be both peripheral, via alterations of histaminergic and/or cholin ergic transmission within the gastrointestinal tract, and central, via modula tion of both ascending visceral sensory afferents and central transmission 191 . SSRIs are generally well toler ated. Adverse effects such as constipation, dry mouth, drowsiness and fatigue are reported with TCAs. TCAs may be particularly effective for treating pain in patients with IBSD, but are less suitable for patients who have IBSC.
Laxatives and motility accelerants. In those with con stipation, simple laxatives such as senna and docusate are often effective in managing symptoms. However, the use of lactulose is not recommended as it is often poorly tolerated by patients with IBS because of wors ening of bloating and discomfort. Linaclotide, a min imally absorbed guanylyl cyclase C agonist peptide (FIG. 8) , can be used as secondline therapy after lax atives have failed in patients with IBSC and symptoms Drugs currently used for the treatment of irritable bowel syndrome (IBS) (orange boxes) target nerve activity, epithelial functions or the contractile state of the smooth muscle layers. Several drugs act by enhancing the activity of chloride channels to increase fluid secretion into the intestinal lumen as a consequence. Other mechanisms of action include modulation of visceral sensitivity at a central or peripheral level. Finally, drugs act to modulate signal transduction at the neuromuscular junction or alter motility by direct myogenic actions. The plus and minus symbols indicate whether a mediator activates or inhibits its target cell; those in parentheses denote actions established in animal models and those without parentheses are effects demonstrated in humans (human tissue). 5-HT, 5-hydroxytryptamine (also known as serotonin); ACh, acetylcholine; CFTR, cystic fibrosis transmembrane conductance regulator; CIC2, chloride channel protein 2; GC-C, guanylyl cyclase C; VIP, vasoactive intestinal peptide.
have lasted for >1 year. Linaclotide has a dual action through increasing intraluminal fluid secretion thereby giving its laxation effect but also an analgesic effect via modulation of colonic nociceptors 192 , and its effects caused reduced abdominal pain, bloating and bowel symptoms in two welldesigned Phase III RCTs 193, 194 . Lubiprostone, a minimally absorbed, locally active, bicyclic fatty acid derivative of prostaglandin E1, acti vates type 2 chloride channels on the enterocyctic apical membrane, thereby stimulating fluid secretion. Lubiprostone has been shown to improve global intes tinal symptoms in IBSC 195 . 5HT4 receptor agonists (such as prucalopride), which promote gut motility through the activation of the serotoninergic pathways, have been shown to be effective in increasing com plete spontaneous bowel movements in patients with chronic constipation 196 .
Antidiarrhoeals. The μopioid receptor agonist lopera mide is frequently used as a firstline agent in IBSD and improves diarrhoea by inducing peristalsis, which prolongs the gastrointestinal transit time. As lopera mide does not cross the blood-brain barrier, central adverse effects are limited. Its main benefit is reducing stool frequency and defaecation urgency, and improv ing the consistency of the stool 197 . Eluxadoline, a mixed μ opioid receptor agonist and δopioid receptor antago nist, has been evaluated in a Phase III RCT, although safety concerns have been expressed concerning the excess rates of pancreatitis 198 . 5HT3 receptor antagonists, such as alosetron, ramosetron and ondansetron, are effective in the management of IBSD symptoms. The mechanism of action of 5HT3 receptor antagonists is complex and incompletely understood, but is considered to pro ceed through inhibition of the ascending excitatory component of the peristaltic reflex and of the high amplitude propagating contractions within the gastro intestinal tract 199 . However, a central effect of 5HT3 receptor antagonists on pain cannot be excluded 200 . Safety concerns, with respect to ischaemic colitis, have been confined to alosetron, which subsequently led to restrictions in its prescription 201 . Consequently, other 5HT3 receptor antagonists have been investigated, with ondansetron 202 and ramosetron demonstrating efficacy in RCTs 203 .
Manipulation of the microbiota. Given the burgeon ing evidence of the role of the microbiota in IBS, both antibiotics and probiotics have been evaluated. The non absorbable antibiotic, rifaximin, has been demonstrated to cause a reduction in symptoms, with a NNT of approximately 11 patients, although it is not clear whether repeated courses of treatment are needed 204 . The mechanisms by which rifaximin exerts its positive effects on IBS symptoms are incom pletely understood and may include modulation of the gut microbiota, but also direct effects on local microinflammation. Rifaximin is approved for use in the United States, but has not yet received regulatory approval in Europe. Probiotics can reduce pain and symptom severity, although recent metaanalyses have highlighted that inconsistencies in study design render definitive recommend ations problematic 183, 184, 205 ; again, it is unclear whether pro biotics act on IBS symptoms through direct modulation of the microbiota, indirect via the gut immune system or otherwise.
Others.
A proportion of patients use herbal supplements either as single herbs or in combination. Four weeks of treatment with iberogast, which is a mixture of nine plant extracts, improved abdominal pain and QOL in a doubleblind RCT of 208 patients with all types of IBS 206 . Although the mechanism of action is poorly understood, it is probably multifaceted via acetylcholine, 5HT and opioid receptors in the gastrointestinal tract 207 . Although herbal remedies represent a promising intervention, fur ther rigorously designed larger RCTs in the subtypes of IBS are needed.
Psychotherapy
The biopsychosocial model of IBS suggests that abdominal symptoms secondarily influence anxiety and depression (bottomup) and psychosocial factors influence physiological factors, such as motor func tion, sensory threshold and stress reactivity of the gut (topdown) 208 . Treatment concepts that target these psycho social factors of patients with IBS should be based on evidence based models that take the following three components into account: altered peripheral regula tion of gut function, altered brain-gut signalling and reducing psychological distress, including general hypervigilance and a general mindset of catastro phizing 209 . Such models might be helpful as a basis of patient education and a target for effective treatments. To further improve treatment programmes, we have to learn more about IBSspecific interactions and the role of stress and visceral sensitivity for clearer evidence on which group of patients might benefit from which treatment approach. In addition, it should be noted that patients with IBS often experience additional functional symptoms, pointing to the complexity of the condition 15 . The effect of IBS symptoms on patients' feelings of shame, fearfulness and embarrassment is well estab lished; patients report being poorly understood by their physicians, as well as by their family members and friends 210 . Patients who experience a positive therapeu tic physician-patient relationship have fewer IBSrelated followup visits 211 . International treatment guidelines for IBS have advocated for a graded treatment approach 212, 213 . The National Institute of Health and Care Excellence (NICE) guidelines advise that patients whose symp toms do not respond to pharmacological treatments after 12 months and who develop a continuing symp tom profile (refractory IBS) should be considered for referral to cognitive-behavioural therapy (CBT), hypno therapy (gutdirected hypnosis) or other psycho logical therapy, such as psycho dynamic (interpersonal) therapy and mindfulnessbased therapy 190 .
BOX 7 describes the four major psychologicalbased therapies for patients with IBS. Several metaanalyses have been performed in the field of psychological and behavioural therapies (including studies in stress reduc tion and relaxation) that took 45 RCTs into account with a total of 3,325 patients with IBS of all subtypes (TABLE 1) . Overall, the NNT for psychological therapies is four patients (95% CI: 3-5) and, therefore, better than the majority of drugs 214 . In a steppedcare approach (begin ning with the least intensive or invasive treatment and stepping up or down depending on the needs of the patients), a psychologybased selfaid (educational) approach has been shown recently in a metaanalysis as an effective treatment option for all subtypes of IBS 250 . Compared with control treatments, a medium effect size was demonstrated on decreased symptom severity and a large effect size on increased patient's QOL.
The best evidence is available for CBT. Although CBT is not routinely available in primary care, it can be accessed in some local hospitals and healthcare systems. There are mediumtolarge significant pooled effect sizes for an improvement of IBS symptoms using CBT with a medium significant pooled effect size for QOL and a smalltomedium pooled effect size for psycho logical comorbid symptoms. The NNT for CBT is only three patients, with a limited variance between the RCTs. Nevertheless, to date there is no evidence of a superiority of CBT compared with other psychological treatments in IBS.
Validation of psychodynamic (interpersonal) ther apy, gutdirected hypnosis and mindfulnessbased therapy (BOX 7) has only been done in a very limited number of tertiary treatment centres and the general ization of these treatment approaches is limited. Finally, mindfulness based therapy for IBS shows some prom ising initial results, particularly in the subgroup of female patients with IBS 215 . Very limited data on multi component thera pies and on the combination of anti depressants and psycho logical treatments are available 169 . Overall, there is a lack of reports of adverse effects of psychological and behavioural treatment approaches and treatment resistance in patients with IBS. Psychological therapies have also regularly not distinguished between IBS subtypes and, thus, might have missed differential indications and advantages and disadvantages.
Quality of life
In the field of medicine, general QOL and disease specific QOL are distinguished. General QOL is a measure of the entire health perception of a person. Representative gen eral QOL can be assessed using the Medical Outcome Study 36item ShortForm Health Survey (SF36) 216 or the EuroQOL survey 217 . SF36 is the most popular instru ment that can evaluate physical functioning, physi cal role, bodily pain, general health perceptions, vitality, social functioning, emotional role and mental health 216 . Diseasespecific QOL is a measure of life disturbance that is specifically caused by the disease 218, 219 . QOL in patients with IBS is greatly disturbed. Patients with IBS showed impaired general QOL with lower values on all SF36 subscales except physical func tioning than healthy controls in one study 220 , whereas lower values on the SF36 subscales in patients with IBS (except physical functioning, physical role and emo tional role) than in healthy controls were observed in another study 221 . All subscales of SF36, except the physi cal functioning and physical role domains, were lower in patients with IBS than in healthy controls regardless of culture 222 . The degree of disturbance of general QOL in patients with IBS has been shown to be worse in several subcategories than in those with gastroesophageal reflux disease, diabetes mellitus or severe chronic kidney dis ease 220 . Finally, a study has shown that patients with IBS had more disturbed general QOL in physical role, bodily pain, general health perceptions and social functioning than nonconsulters with IBS (individuals who do not seek treatment) 221 . QOL seems to be the same among IBS subtypes. However, diseasespecific QOL, as measured with the IBSQOL in patients with IBSD or IBSM, was worse than in patients with IBSC in one study 222 . In this study, increased food avoidance in patients with IBSD and IBSM may have been responsible for the lower QOL 222 , but there are controversial reports 218 . In severe IBS, both gastrointestinal symptoms and psychiatric comorbidity independently contribute to disturbed QOL 223 (FIG. 9) . Another study revealed that the QOL of patients with IBS was more influenced by the extraintestinal symptoms -such as tiring easily, low in energy, the feeling that there is something is based on the assumption that irritable bowel syndrome (IBS) symptoms are a response to stressful life events, maladaptive behaviour and an inappropriate attribution of symptoms. CBT aims to modify these behaviours and thoughts through education, which consists of the explanation of IBS symptoms and the CBT model, and by identification of the psychological factors that are interacting with their physical symptoms. On the basis of these findings, patients and therapists work together to identify the potential associations between IBS symptoms and their thoughts, emotions and actions. Finally, behavioural therapy (for example, stress management) is applied 245 .
Psychodynamic (interpersonal) therapy
Psychodynamic (interpersonal) therapy (PIT) aims to obtain insights into symptom development as a consequence of interpersonal conflicts or difficulties in relationships with key people. Patients are encouraged to discuss their symptoms in depth, emotional factors are explored and links between symptoms and emotional factors are identified 246 .
Gut-directed hypnosis
In gut-directed hypnosis (GDH), as opposed to standard hypnotherapy, suggestions are made on how to control and normalize gastrointestinal function and metaphors are used to bring about improvement. GDH differs from other forms of psychological treatment in which therapy is provided to patients in a conscious state. After information on the effects of hypnosis is given, participants are provided with a compact disk (created by hypnotherapists) for practicing at home on a daily basis 247 .
Mindfulness-based therapy
Mindfulness-based therapy (MBT) for IBS has been adapted from the mindfulness-based stress reduction programme. The basic course emphasizes the relevance of mindfulness in coping with IBS-related symptoms and perceptions. With a range of behavioural and cognitive techniques, MBT promotes sensory versus emotional processing of interoceptive signals and counteracts catastrophizing as a maladaptive cognitive coping style 215 .
seriously wrong with their body, feeling tense, feeling nervous, feeling hopeless, difficulty sleeping and low sexual interest -than by gastrointestinal symptoms 224 . The psychological and psychosocial dimensions of food ingestion might also have a role. Eating with family and friends is probably the most common form of social interaction worldwide. An inability to participate in such a fundamental component of social intercourse because of a fear of pain, urgency, diarrhoea or disten sion occurring during or immediately after a meal can be devastating and can result in social isolation 210 . Systematic reviews have clarified that improvement of IBSrelated pain by treatment results in better QOL in patients with IBS 225 . The diseasespecific IBSQOL and IBSQOL questionnaires can measure the efficacy of treatment, especially longterm therapies 226 . Although the SF36 can also detect the efficacy of longterm treat ment (>1 year), it is less sensitive than the IBSQOL. Both measures struggle to detect drug or psycho therapy efficacy in the short term (<1 month) 226, 227 , but IBS QOL is sensitive enough to detect efficacy for midterm (3 months) treatment 203 . A therapeutic gain of ≥14 points in IBSQOL denotes a clinically meaningful change. Even if primary end points based on cardinal symptoms of IBS are similar between treatments, a treatment result ing in better QOL may be preferred by patients over another treatment that does not improve QOL.
Outlook
The field of research into IBS has expanded consider ably over the past decade with many new studies, in part driven by the development of new therapeutic agents. This trajectory seems likely to continue as patients with IBS account for a substantial proportion of all gastro intestinal consultations, and many questions in the field remain unanswered
.
Patient stratification and biomarkers
Many classes of drugs have been evaluated by RCTs in IBS and these have often produced disappointingly small differences from placebo 187, 214, 228 . These small differences conceal the fact that some patients benefit from the drugs. • NNT for dynamic psychotherapy was 3.5 (95% CI: 2-25)
• PIT is less well standardized in terms of its performance (that is, duration, setting and phases) GDH 247 7 RCTs (452) • 6 of 7 RCTs reported a significant reduction (all P < 0.05) in overall gastrointestinal symptoms compared with supportive therapy only • Response rates ranged between 24% and 73% • Efficacy was maintained long term in four of five studies • NNT was 4 (95% CI: 3-8)
• Very few professionals are trained for the specific implementation of GDH and therefore their services can be difficult to access • The mechanisms by which GDH exerts its effect are poorly understood MBT 215 2 RCTs (79)
• Women showed greater reductions of symptoms compared with a control group immediately after training (26.4% versus 6.2%; P = 0.006) and at 3 months follow-up (38.2% compared with 11.8%; P = 0.001) • Changes in QOL, distress and anxiety were not different between groups immediately after treatment • Significantly greater improvement in the MBT group than in the control group evident at 3 months follow-up • The beneficial effects persisted for ≥3 months
• In another RCT, the IBS symptom severity in the mindfulness-based stress reduction group was not retained at 6 months follow-up • GSHs might be an easily accessible and a cost-effective treatment alternative. However, there is a wide heterogeneity and variance in its performance
The NNT data are based on Ford et al. 214 . CBT, cognitive-behavioural therapy; GDH, gut-directed hypnosis; GSH, guided self-help intervention; IBS, irritable bowel syndrome; MBT, mindfulness-based therapy; NNT, number needed to treat; OR, odds ratio; PIT, psychodynamic (interpersonal) therapy; QOL, quality of life; RCT, randomized controlled trial. *See REF. 245 . Proper stratification of patients by relevant underlying disease mechanism has been an issue, therefore many trials use unselected patients with IBS, independent of the underlying disease mechanisms and clinical presenta tions. The use of 5HT receptormodulating drugs has taught the research community that restricting 5HT3 receptor antagonists to patients without constipation improved their effectiveness with significant differences from placebo 229, 230 , owing to the fact that 5HT3 recep tor antagonists slow transit and aggravate constipation. However, RCTs rarely measure transit as a requirement for trial entry, which depends on symptoms recorded in daily symptom diaries. The use of moreobjective bio markers to select patients for RCTs would be expected to improve the effect size and reduce the number needed to test to show a significant difference from placebo.
The lack of reproducible, widely available biomark ers that reflect the targets of 'older' drugs has been a considerable limitation. Antispasmodics are a good example of such drugs that have fallen out of favour because we cannot reliably identify those with excessive motor activity who might be expected to respond. Future novel noninvasive motility assessments, such as MRI 231 , capsule endoscopy 232 and the pressure sensitive, temperaturesensitive and pHsensitive SmartPill (Given Imaging Ltd, Yoqneam, Israel) 233 (which can measure intestinal contractions), hold the possibility of identifying such patients in the future.
Although individual genetic markers seem likely to be associated with only quite modest increases in risk for IBS, they might be important predictors of drug sen sitivity in particular pathways. 5HT3 receptor antago nists are good examples of drugs with a wide range of sensitivities such that effective doses for one patient can produce unacceptable constipation in another. This finding may be due to a combination of important functional polymorphisms in genes involved in 5HT synthesis (tryptophan hydroxylase 1 (TPH1)), those involved in 5HT reuptake via the 5HT transporter (SLC6A4) and polymorphisms in the 5HT3 receptor genes (which alter sensitivity). Several small studies have suggested signifi cant differences in responder status to one 5HT3 receptor antagonist, ramosetron, according to polymorphisms in TPH1 (REF. 234) and to another 5HT3 receptor antagonist, alosetron, accord ing to polymorphisms in SLC6A4 (REF. 235 ). However, these studies are underpowered and have not yet been reproduced 202 . By analogy with other complex dis orders 236 , the effect of any one individual polymorphism may be limited but combining polymorphisms that pre dict low 5HT production with rapid uptake and low receptor sensitivity would be expected to be associated with higher odds ratios for success of 5HT manipula tion. Future studies should be powered to examine this notion such that the dose can be tailored to individ ual patients. Similarly, polymorphisms in the FGF19-FGFR4 pathway, which controls bile acid synthesis 107, 108 , influence colonic transit and should be explored to see if different combinations alter sensitivity to bile acid sequestrants or bile acid transporter inhibitors.
Mode of action of food intolerances
Dietary restrictions such as low FODMAP diets (BOX 5) are another example in which implementation of an effective treatment is hampered by lack of biomarkers to predict response or reliably identify the key com ponent (or components) of food that are responsible for symptoms. Although poorly absorbed fermentable carbo hydrates can undoubtedly cause symptoms in some patients, visceral sensitivity is the key to why some individ uals experience symptoms and some do not 237 , at least in the case of lactose malabsorption. However, no trial of lactose exclusion in IBS has used measures of sensitivity to stratify patients. While rectal barostat tests to assess visceral sensitivity are difficult, although not impossible to standardize across centres, alternatives might be to use simple cutaneous pressure or thermal stimulation 238 . More remotely, somatization question naires concerning nongastrointestinal symptoms such as headache, backache, dyspnoea and palpitations have been shown to correlate, albeit weakly, with rectal distension pressure thresholds for pain 239 . Figure 9 | Concept of multifactorial quality-of-life effects in IBS. The genome and epigenome partially determine ('filter') the response of an individual to external stressors (psychosocial factors) and internal stressors (ingested food or microbiota). These, together with social support, appraisal, emotion and coping behaviours against stressors, determine the stress response affecting the brain-gut interactions. This response might involve regional brain activation, changes in autonomic and neuroendocrine function, which might lead to many of the clinical manifestations observed in irritable bowel syndrome (IBS), including visceral hypersensitivity, alteration in gastrointestinal motility, increased mucosal permeability and low-grade inflammation. These gastrointestinal symptoms and other extra-intestinal manifestations (such as multiple somatic symptoms and psychiatric comorbidities) impair the quality of life (QOL) of patients with IBS.
The physical form of food is another key variable whose importance is yet to be defined. Many of the diet ary components implicated in IBS symptoms are actu ally consumed as solids and hence delivered into the duo denum more slowly after trituration by antral con tractions. The rapid entry of osmotically active poorly absorbed substrates -mainly in liquid form -such as lactose in a patient with lactose malabsorption 240, 241 or mannitol in healthy volunteers 241 result in a rapid influx of water into the small intestine, which probably stimulates transit and rapid delivery into the colon. This leads to the virtually instantaneous generation of gas 242 , mainly hydrogen, given that the microbiota are unable to fully metabolize the sudden excess of substrate. Furthermore, distension of the ascending colon generates propul sive colonic motility, which a sensitized individual may experi ence as cramps; a slower delivery in a solid matrix may be better tolerated. Future studies should define how the physical form of FODMAPs alters their tolerability, which would allow a less restrictive diet that may be easier to follow and, hence, more widely adopted than at present.
Functional effect of changes in microbiota
Many studies have found profound differences in the microbiota of selected patients with IBS, but the agree ment on the involved species between studies is poor 57 . Given the very large number of different species that have overlapping metabolic capabilities and functional effects, focusing on function may be more helpful than just identifying the species present.
Analysis of urine and stool metabolites, including bile acids and endogenous tryptase, may provide simpler bio markers of function that could predict responsiveness to microbiota manipulation. Thus, low levels of butyrate, a SCFA, might encourage the provision of prebiotics that favour butyrateproducing bacteria, such as Eubacterium rectale and Roseburia cecicola. Future studies should also take into account the important role of transit time and its variability. The challenge of rapid transit favours organ isms with either enhanced growth capacity or those that adhere to the mucosa to deal with rapid flow within the colon 243 , although, these results need to be replicated and studied in more detail to enable dissection of the extent to which differences in microbiota are the cause or the effect of rapid transit. Better insight might also enable the tailoring of diet to the existing microbiota in a patient, based on their metabolic capabilities and response to a substrate provided in the diet. 
